4D Molecular Therapeutics Stock (NASDAQ:FDMT)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$8.67

52W Range

$7.32 - $36.25

50D Avg

$10.17

200D Avg

$20.37

Market Cap

$388.77M

Avg Vol (3M)

$846.25K

Beta

2.80

Div Yield

-

FDMT Company Profile


4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

147

IPO Date

Dec 11, 2020

Website

FDMT Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Collaboration And License Revenue$20.01M$3.13M$18.04M

Fiscal year ends in Dec 23 | Currency in USD

FDMT Financial Summary


Dec 23Dec 22Dec 21
Revenue-$3.13M$18.04M
Operating Income$-112.87M$-110.03M$-71.33M
Net Income$-100.84M$-101.08M$-68.30M
EBITDA$-112.87M$-110.03M$-71.33M
Basic EPS-$-3.12$-2.46
Diluted EPS-$-3.12$-2.46

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
AKROAkero Therapeutics, Inc.
GOSSGossamer Bio, Inc.
CGEMCullinan Oncology, Inc.
RVMDRevolution Medicines, Inc. Warrant
MLYSMineralys Therapeutics, Inc.
EWTXEdgewise Therapeutics, Inc.
BMEABiomea Fusion, Inc.
STOKStoke Therapeutics, Inc.
IPSCCentury Therapeutics, Inc.
BDTXBlack Diamond Therapeutics, Inc.
REPLReplimune Group, Inc.
BCELAtreca, Inc.
KRONKronos Bio, Inc.
PASGPassage Bio, Inc.
CCCCC4 Therapeutics, Inc.
FIXXQ32 Bio Inc.
LYRALyra Therapeutics, Inc.
NVCTNuvectis Pharma, Inc.